A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease

a study on Prostate CancerCardiovascular Disease

Summary

for males (full criteria)
at Orange, California and other locations
study started
estimated completion

Description

Summary

The purpose of this trial is to test if a marketed drug for advanced prostate cancer (FIRMAGON) can reduce the risk of cardiovascular complications as compared to another marketed drug for advanced prostate cancer (LUPRON DEPOT) in patients with prostate cancer and cardiovascular disease.

Official Title

A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients With Prostate Cancer and Cardiovascular Disease Receiving Degarelix (Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist)

Keywords

Prostate CancerProstatic NeoplasmsCardiovascular DiseasesLeuprolideDegarelix

Eligibility

You can join if…

Open to males

  • Advanced prostate cancer
  • Indication to initiate androgen deprivation therapy (ADT)
  • Predefined cardiovascular disease

You CAN'T join if...

  • Previous or current hormonal management of prostate cancer (unless terminated at least 12 months prior to trial)
  • Acute cardiovascular disease in the previous 30 days

Locations

  • University of California, Irvine Medical Centeraccepting new patients
    OrangeCalifornia92868United States
  • Pacific Cancer Medical Center, Inc.accepting new patients
    AnaheimCalifornia92801United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Ferring Pharmaceuticals
ID
NCT02663908
Phase
Phase 3
Study Type
Interventional
Last Updated